Search 

Etteplan supports Medtech companies with design and development. ISO 13485 certified our 70 consultant engineers and designers help large and small companies develop products in all MDD Classes I-III from idea to production. Offices are located in Stockholm, Uppsala, Halmstad, Lund, Copenhagen and Helsinki offering the following engineering skills: Usability, Innovation Workshops, Industrial Design, Mechanical Engineering, Hardware/Software Development, Project Management, Regulatory Affairs and Documentation

We want to improve the quality of life for 660.000 epilepsy families. (# is the western world only)

We want to give New Freedom and Peace of Mind to patients, parents, and health care professionals.

IctalCare A/S develops and markets a body-worn wireless epilepsy seizure alarm that help people with epilepsy, caregivers and healthcare professional

IctalCare 365 consist of a;
- Disposable electrode
- Reusable detector "Senses"
- Reusable A-Unit (receiver and transmitter)

Timeline;
- Launch 12.12.12 at 12.12 pm in Denmark
- Launch 12th of April 2013 in UK and Germany
- Launch 12th of April 2014 in USA
- Exit 2016

Finance;
- Expected revenue in 2016 is € 23 Million
- Positive cash flow from 2014 - 2015
- Expected EBITDA is € 9.3 Million in 2016 having a gross Margin of 55 %

Business Model
We have Sustainable Competitive Advantage using the Razor blade Model. The disposable electrodes secures a continuous sale and only IctalCare electrodes fit to the reusable "Senses" detector.

The Business Model is designed around a monthly subscription Model however buy on demand will also be possible

KIPAX is a private investor specialized into Medtech and was founded 2010.

Investments have been made for instance into SenseAbues (breath based drug testing), Contego (Embolic Protection Devices), AEEG (Cardiac surgical devices), Zoomcamp (vehicle for disabled persons), and others.

We prefer to invest into early phase startup companies as a co-investor, but not a lead investor.

KIPAX is working in close cooperation with KIPA, a Swedish based IP firm specialized into medical devices.

KIPAX is scouting for new investemnt projects and is  this year represented by Erik Krahbichler.

Likvor AB

Likvor is a medical device company which has developed a system to be used in neurological investigations assessing cerebrospinal fluid (CSF) dynamics. The LIKVOR CELDA® SYSTEM is on the market today.

Product

Likvor’s core product, the CELDA® Instrument is a device to measure the dynamics of the cerebrospinal fluid (“CSF”) system. With increased understanding of the brain and neurological diseases, mapping CSF dynamics is becoming more and more important. CELDA® Instrument offers automatic and standardized protocols for multiple purposes in the diagnostic process – identifying patients suffering from normal pressure hydrocephalus (“NPH”) with dementia like symptoms, mapping CSF dynamics pre- and post-shunt surgery, shunt control, constant flow or constant pressure measurements, tap tests, bolus infusions etc. It is the first and only CE certified instrument in this field and will enable objective comparisons of research data from different clinics and research groups. With its flexibility and easy handling the CELDA® sets a new standard for investigations of CSF-dynamics. CELDA® Instrument is safer for the patient and yields a faster and more accurate diagnosis.

By using the LIKVOR CELDA® SYSTEM hospitals can make huge savings, in costs as they reduce the number of shunt reoperations, and in human suffering.

Likvor AB is marketing the LIKVOR CELDA® SYSTEM and LIKVOR CELDA® TOOLS. The system includes an instrument, a bed and a disposable tube set. The system is the result of over 40 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. The company has one patent in the US and two patents pending which includes both method and device.

Potential and the market

Statistics show that 1 in 10 dementia patients suffer from NPH. Studies indicate that approximately 1.4 million patients in Europe, USA and Japan suffer from NPH.

The CELDA® SYSTEM was CE certified in 2009, and currently there are 8 systems in clinical use with paying customers in Sweden, Denmark, Finland and the UK. To reach the European market, distributors will be used, two contracts are signed; for the German- and the UK-market. A potential clinical study in the US is being evaluated.

Next step

Likvor is looking for 20 MSK for the next three years. The capital will be used to speed up the market penetration in Europe and recruit sales personnel. Exit could be possible through an industrial buyout, for example from a shunt company.  

Synergus is a MedTech Consulting Company in Reimbursement & Health Economics and Quality & Regulatory

Unisensor is seeking investors for the development, clinical evaluation and launch of a new instrument for antibiotic susceptibility testing.

Sepsis (blood poisoning) is a serious medical condition that in US alone kills more than 100,000 annually, surpassing the number of deaths from acute myocardial infarction (AMI), stroke, or cancer. Once detected, it is paramount to initiate the proper antibiotic therapy as soon as possible, since survival chance decrease by the hour. In addition septicaemia patients is a substantial economic burden to the hospital – according to one source up to 50.000 USD per patient. Traditional AST typically takes from 15-30 hours, and Unisensor has shown that this can be decreased to less than one hour by using our patented technology. This will not only increase the survival chance and reduce the costs, but also have the societal benefit, that the emergence of multi-resistant bacteria is reduced due to the earlier usage of the proper narrow-band antibiotic therapy.

To finance the instrument development, clinical evaluation and initial sales and marketing activities Unisensor is seeking investors to enter into a joint venture or or other financial collaboration or partnership.